{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:03:17Z","timestamp":1787162597381,"version":"build-2736575974"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Pandemic Influenza Scientific Agenda (PISA)"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.antiviral.2016.01.009","type":"journal-article","created":{"date-parts":[[2016,1,22]],"date-time":"2016-01-22T15:59:27Z","timestamp":1453478367000},"page":"28-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Standardizing the influenza neuraminidase inhibition assay among United States public health laboratories conducting virological surveillance"],"prefix":"10.1016","volume":"128","author":[{"given":"M.","family":"Okomo-Adhiambo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.P.","family":"Mishin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sleeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Saguar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Reisdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.H.","family":"Griesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.J.","family":"Spackman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mendenhall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.","family":"Carlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Healey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"St. George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Laplante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Aden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.V.","family":"Gubareva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2016.01.009_bib1","unstructured":"CDC Website. Fluview http:\/\/www.cdc.gov\/flu\/weekly\/. (accessed 09.10.15.)."},{"key":"10.1016\/j.antiviral.2016.01.009_bib2","unstructured":"Clinical Trials.Gov Website https:\/\/clinicaltrials.gov\/show\/NCT01231620. (accessed 09.10.15.)."},{"issue":"5","key":"10.1016\/j.antiviral.2016.01.009_bib3","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1586\/erm.09.21","article-title":"Influenza genome analysis using pyrosequencing method: current applications for a moving target","volume":"9","author":"Deyde","year":"2009","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"2","key":"10.1016\/j.antiviral.2016.01.009_bib4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1086\/518936","article-title":"Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide","volume":"196","author":"Deyde","year":"2007","journal-title":"J.\u00a0Infect. Dis."},{"issue":"6","key":"10.1016\/j.antiviral.2016.01.009_bib30","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/infdis\/jis776","article-title":"A cluster of patients infected with I221V influenza B virus variants with reduced oseltamivir susceptibility--North Carolina and South Carolina, 2010\u20132011.","volume":"207","author":"Garg","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.01.009_bib5","unstructured":"IRR Website. http:\/\/www.influenzareagentresource.org\/Catalog.aspx. (accessed 09.10.15.)."},{"key":"10.1016\/j.antiviral.2016.01.009_bib6","unstructured":"ISIRV Antiviral Group Website. http:\/\/www.isirv.org\/site\/index.php\/reference-panel. (accessed 30.11.15.)."},{"issue":"7","key":"10.1016\/j.antiviral.2016.01.009_bib7","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1128\/AAC.47.7.2264-2272.2003","article-title":"Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir","volume":"47","author":"McKimm-Breschkin","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.01.009_bib8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.antiviral.2014.12.004","article-title":"Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation","volume":"114","author":"McKimm-Breschkin","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.01.009_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.antiviral.2014.07.001","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013","volume":"110","author":"Meijer","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.01.009_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2013.11.001","article-title":"The effect of the MDCK cell selected neuraminidase D151G mutation on the drug susceptibility assessment of influenza A(H3N2) viruses","volume":"101","author":"Mishin","year":"2014","journal-title":"Antivir. Res."},{"issue":"7","key":"10.1016\/j.antiviral.2016.01.009_bib11","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1128\/AAC.01339-05","article-title":"Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use","volume":"50","author":"Monto","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1\u20132","key":"10.1016\/j.antiviral.2016.01.009_bib12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.virusres.2004.02.033","article-title":"Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons","volume":"103","author":"Mungall","year":"2004","journal-title":"Virus Res."},{"issue":"9","key":"10.1016\/j.antiviral.2016.01.009_bib13","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1128\/AAC.00581-10","article-title":"Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays","volume":"54","author":"Nguyen","year":"2010","journal-title":"Antimicrob. Agents. Chemother."},{"issue":"1","key":"10.1016\/j.antiviral.2016.01.009_bib31","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3201\/eid2101.141006","article-title":"Oseltamivir-resistant influenza A(H1N1)pdm09 viruses, United States, 2013\u201314.","volume":"21","author":"Okomo-Adhiambo","year":"2015","journal-title":"Emerg. Infect. Dis."},{"issue":"2","key":"10.1016\/j.antiviral.2016.01.009_bib14","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/irv.12215","article-title":"Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of WHO antiviral working group criteria","volume":"8","author":"Okomo-Adhiambo","year":"2014","journal-title":"Influenza Other Respir. Viruses"},{"issue":"5","key":"10.1016\/j.antiviral.2016.01.009_bib15","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/irv.12113","article-title":"Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season","volume":"7","author":"Okomo-Adhiambo","year":"2013","journal-title":"Influenza Other Respir. Viruses"},{"key":"10.1016\/j.antiviral.2016.01.009_bib16","series-title":"Proc. South East SAS Users Group Conference: Paper TU04","article-title":"An overview of non-parametric tests in SAS\u00ae: when, why and how","author":"Pappas","year":"2004"},{"issue":"2","key":"10.1016\/j.antiviral.2016.01.009_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1586\/eri.11.174","article-title":"Peramivir for the treatment of influenza","volume":"10","author":"Shetty","year":"2012","journal-title":"Expert Rev. Anti. Infect. Ther."},{"issue":"9","key":"10.1016\/j.antiviral.2016.01.009_bib18","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/AAC.00555-08","article-title":"Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008","volume":"52","author":"Sheu","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.antiviral.2016.01.009_bib19","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3201\/eid1909.130724","article-title":"R292K substitution and drug susceptibility of influenza A(H7N9) viruses","volume":"19","author":"Sleeman","year":"2013","journal-title":"Emerg. Infect. Dis."},{"issue":"4","key":"10.1016\/j.antiviral.2016.01.009_bib20","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1128\/AAC.02556-13","article-title":"Antiviral susceptibility of variant influenza A(H3N2)v viruses isolated in the United States from 2011 to 2013","volume":"58","author":"Sleeman","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.antiviral.2016.01.009_bib21","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2014.19.1.20666","article-title":"A\u00a0community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013","volume":"19","author":"Takashita","year":"2014","journal-title":"Euro Surveill."},{"issue":"5","key":"10.1016\/j.antiviral.2016.01.009_bib22","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1128\/AAC.04836-14","article-title":"Characterization of a large cluster of influenza A(H1N1)pdm09 viruses cross-resistant to oseltamivir and peramivir during the 2013-2014 influenza season in Japan","volume":"59","author":"Takashita","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.01.009_bib23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.antiviral.2015.02.003","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014","volume":"117","author":"Takashita","year":"2015","journal-title":"Antivir. Res."},{"issue":"12","key":"10.1016\/j.antiviral.2016.01.009_bib24","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1128\/AAC.01364-13","article-title":"Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment","volume":"57","author":"Tamura","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.antiviral.2016.01.009_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/(SICI)1099-1654(200001\/02)10:1<45::AID-RMV265>3.0.CO;2-R","article-title":"Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors","volume":"10","author":"Tisdale","year":"2000","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2016.01.009_bib26","unstructured":"Tocris Website http:\/\/www.tocris.com\/molarityCalculator.php. (accessed 09.10.15.)."},{"issue":"2","key":"10.1016\/j.antiviral.2016.01.009_bib27","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1128\/JCM.41.2.742-750.2003","article-title":"Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network","volume":"41","author":"Wetherall","year":"2003","journal-title":"J.\u00a0Clin. Microbiol."},{"issue":"39","key":"10.1016\/j.antiviral.2016.01.009_bib28","first-page":"369","article-title":"Meetings of the WHO working group on surveillance of influenza antiviral susceptibility \u2013 Geneva, November 2011 and June 2012","volume":"87","author":"World Health Organization","year":"2012","journal-title":"Wkly. Epidemiol. Rec."},{"issue":"1","key":"10.1016\/j.antiviral.2016.01.009_bib29","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1128\/AAC.00333-08","article-title":"CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity","volume":"53","author":"Yamashita","year":"2009","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216300110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354216300110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T21:29:45Z","timestamp":1537046985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354216300110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":31,"alternative-id":["S0166354216300110"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.01.009","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Standardizing the influenza neuraminidase inhibition assay among United States public health laboratories conducting virological surveillance","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}